Abstract:e24281 Background: Targeted therapy for patients of NSCLC with HER2 mutations is still on unmet need in clinical setting. Pyrotinib, a HER2 and EGFR tyrosine kinase inhibitor, has showed encouraging anti-tumor effect with a ORR of 54.5% (6/11) in our preliminary data of phase 2 trial. This study aimed to investigate the anti-cancer effect and the potential different mechanism of pyrotinib in organoids and PDX models with HER2 mutation, compared with the other anti-HER2 drugs, afatinib and T-DM1. Methods: Organoids and PDX models were established from the therapeutic naïve patient with HER2-mutant lung cancer. Anti-tumor efficacy,and downstream signaling pathways inhibition were analyzed and compared in afatinb, T-DM1 and different dose of pyrotinib groups in both the organoids and PDX models. Results: Patient-derived organoids and xenografts were established from a 42-year-old female with HER2-A775_G776YVMA-inserted advanced lung adenocarcinoma. When the organoids were treated with afatinib and pyrotinib, at 29nM and 180nM respectively(adopted from the plasma concentrations of previous phase 1 clinical trials) , pyrotinib significantly inhibited the cell growth compared with afatinib(p = 0.0038). The in vivo PDX model study showed that pyrotinib(mouse,80mg/kg,adopted from clinical trial recommended dose) showed a significantly superior anti-cancer effect than afatinib of 15 mg/kg (p = 0.0471), T-DM1 of 10 mg/kg (p = 0.0138) and lower dose of pyrotinib 5 mg/kg(p = 0.0001) and 20 mg/kg(p < 0.0001). Pyrotinib(80mg/kg) also showed a robust ability to inhibit pHER2, pERK and pAkt both in the IHC and western blot analysis. Meanwhile, the body weight of PDX model mice receiving afatinib of 15mg/kg showed a significantly decrease compared with pyrotinib of 80mg/kg(p < 0.0001). Conclusions: Pyrotinib, afatinb and T-DM1 all showed the ability to inhibit HER2 in lung cancer models, while pyrotinib showed a significantly better tolerance and anti-cancer effect than afatinib and T-DM1, which might contribute the encouraging results of our previous phase 2 trial.

Figure S1 from Use of <i>ex</i> <i>vivo</i> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <i>her2</i> Mutant Non–Small Cell Lung Cancer

Supplementary Figure 3 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure from Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy

Comparison the Anti-Tumor Effect of Pyrotinib, Afatinb and T-DM1 in Lung Cancer Organoids and PDX Models with HER2 Mutation.

Supplementary Figure S6 from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

Supplementary Figure S2 from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

Assessment of a Novel VEGF Targeted Agent Using Patient-Derived Tumor Tissue Xenograft Models of Colon Carcinoma with Lymphatic and Hepatic Metastases

Supplementary Figure 1 from Detection and Dynamic Changes of <i>egfr</i> Mutations from Circulating Tumor DNA As a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology

Supplementary Figure 7 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 6 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice

Supplementary Figure 4 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice

Supplementary Figure 5 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice

Supplementary Figure S1 from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

Supplementary Figures from Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer

Supplementary Figure 9 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 1 from <sup>18</sup>F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figure S5 from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

Supplementary Figure 2 from <sup>18</sup>F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Figure S1 from Use of &lt;i&gt;ex&lt;/i&gt; &lt;i&gt;vivo&lt;/i&gt; Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for &lt;i&gt;her2&lt;/i&gt; Mutant Non–Small Cell Lung Cancer